Marta Sitges

Sep 11, 2024 | radcliffecardiology.com | Richard E. Pratley |Phyo T. Htoo |Julia Grapsa |Marta Sitges

Skip to main content Video Published: Views: 14 Likes: 0 Average (ratings) EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes. Interview Questions:1. What was the reasoning for this study? 2.

Sep 11, 2024 | radcliffecardiology.com | Richard E. Pratley |Julia Grapsa |Marta Sitges |Alison J Duncan

Skip to main content Video Published: Views: 22 Likes: 0 Average (ratings) EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial. Interview Questions:1. What is the reasoning behind the FLOW Trial? 2. What was the patient population and study design? 3. What are the key results? 4.

Sep 9, 2024 | radcliffecardiology.com | Joost Daemen |David Erlinge |Julia Grapsa |Marta Sitges

Video Published: Views: 53 Likes: 0 Average (ratings) One-year outcomes from INFINITY-SWEDEHEART RCT recently presented at ESC 2024 demonstrated that DynamX Bioadaptor meets primary endpoint and significantly reduces adverse events compared to DES after six months. Dr David Erlinge, the primary investigator of INFINITY-SWEDEHEART RCT, shares a quick summary of the one-year outcomes presented at ESC 2024.

Sep 6, 2024 | radcliffecardiology.com | John McMurray |Richard E. Pratley |Julia Grapsa |Marta Sitges

Skip to main content Video Published: Views: 9 Likes: 0 Average (ratings) Join Prof Atul Pathak (Clinique Pasteur, FR) and Prof Sofie Brouwers (Olv Hospital Aalst, BE) in this video on 'Renal Denervation Takeaways From ESC Guidelines'. This video is supported by Related content